These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39289716)

  • 1. Immune-related [
    Santo G; Cucè M; Restuccia A; Del Giudice T; Tassone P; Cicone F; Tagliaferri P; Cascini GL
    Cancer Imaging; 2024 Sep; 24(1):125. PubMed ID: 39289716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organ-specific accuracy of [
    Gideonse BM; Birkeland M; Vilstrup MH; Grupe P; Naghavi-Behzad M; Ruhlmann CH; Gerke O; Hildebrandt MG
    Jpn J Radiol; 2024 Jul; 42(7):753-764. PubMed ID: 38504000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total metabolic tumor volume on
    Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors.
    Serino M; Freitas C; Martins M; Ferreira P; Cardoso C; Veiga F; Santos V; Araújo D; Novais-Bastos H; Magalhães A; Queiroga H; Fernandes G; Hespanhol V
    Pulmonology; 2024; 30(4):352-361. PubMed ID: 35414494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of
    Ling T; Zhang L; Peng R; Yue C; Huang L
    Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
    JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim [
    Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
    J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging.
    Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
    Q J Nucl Med Mol Imaging; 2022 Sep; 66(3):245-254. PubMed ID: 35612369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the role of colonic and other anatomical sites uptake by [
    Rizzo A; Cantale O; Mogavero A; Garetto L; Racca M; Venesio T; Anpalakhan S; Novello S; Gregorc V; Banna GL
    Thorac Cancer; 2023 Aug; 14(24):2473-2483. PubMed ID: 37442801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors.
    Hata H; Matsumura C; Chisaki Y; Nishioka K; Tokuda M; Miyagi K; Suizu T; Yano Y
    Cancer Control; 2022; 29():10732748221130576. PubMed ID: 36254804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M
    Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.